

# FDG-PET/CT and Multimodal Machine Learning Model Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer


Groheux D, et al. Cancers (Basel). 2025; 17(7):1249.  
doi: 10.3390/cancers17071249

## KEY OUTCOMES


Applying machine learning (ML)-based method to baseline multimodal data helps predict pathological complete response (pCR) status after neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC) patients and may identify correlations with improved long-term outcomes.

The integration of clinical, histopathological, molecular, imaging, and radio-mic features resulted in a robust AI-powered predictive model, that can allow for precision medicine and effective treatment decisions.


## BACKGROUND



TNBC is a heterogeneous and aggressive subtype of breast cancer associated with poor outcomes



pCR status after NAC strongly correlates with favourable long-term outcomes



Predicting pCR based on patient baseline multi-modal data is of clinical interest to guide the treatment regimen

## OBJECTIVES




**Evaluate a multimodal machine learning-based algorithm predictive of pCR**



**Predict response to NAC based on baseline data from breast cancer patients**

## METHODS & APPROACH



## FINDINGS

The best results in **the prediction of pCR status after NAC** were obtained with **a support vector machine (SVM) algorithm with a linear kernel, aggregating baseline clinical data, histopathological and molecular features, and PET data, including radiomic features.**

**AUC | 0.82**

95% CI [0.74; 0.90]

Excluding a specific data modality resulted in a **decrease of almost 10% in the AUC.**


Datasets	AUC (95%CI)
Set 1	0.63 [0.51; 0.73]
Set 2	0.70 [0.60; 0.80]
Set 3	0.82 [0.74; 0.90]

Set 1: Clinical, histopathological, and PET non-radiomic features; Set 2: Set 1 + genomic data; Set 3: Set 2 + whole set of radiomic features

The **three features with the highest weight in the algorithm** were:

- Tumor SUVmax, 2 radiomic features
- GGIr
- Clinical T-stage

SUV: standardized uptake value; GGIr: genomic grade index



**Patients with predicted pCR showed a longer event-free survival (EFS) than patients with predicted non-pCR (p=0.09, likely due to the small size of the cohort).**

### CLINICAL IMPACT OF AI PREDICTIVE APPROACHES

Predictive AI-based approaches have shown the ability to improve breast cancer treatment management by allowing an earlier identification of patients' response to chemotherapy, leading to a more personalized treatment.



→ May benefit from reducing treatment

→ May benefit from the addition of immunotherapy or dose intensification

■ TNBC patients predicted to achieve pCR after NAC

■ TNBC patients not predicted to achieve pCR after NAC

The results of this proof-of-concept study are in line with what previous studies have shown, and it highlights the **importance of a truly multimodal analysis, to improve patient outcomes.**

This project was executed by SOPHiA GENETICS in collaboration with **AP-HP Hôpital Saint Louis and INSERM.**